Oftentimes it’s hard for me to see the forest through the trees. Being responsible for the commercial outcome of what we are working to accomplish at Advera Health with an incredibly talented, albeit small, team can be daunting at best. At worst it is completely insanely chaotic. Ensuring sales forecasts are accurate for board and investor meetings, directing the marketing strategy for product launches like this week’s announcement of our multiple sclerosis coverage, and working out the details of big partnerships like the one we will soon be announcing with a large, national group purchasing organization (GPO) requires a lot of attention to detail, acutely managed with a long to-do list.
It’s those details of everyday business that can obscure the bigger picture. At the risk of sounding braggadocio, what we are doing at Advera Health is important.
This importance became clearer to me earlier this week. After putting our eight month old daughter to bed, my wife, a registered nurse in the MICU, and I were enjoying a much needed glass of wine and I was attempting to explain to her what we’ve built with Evidex and how I was excited that we were launching coverage of multiple sclerosis medications.
Her reaction, much to my chagrin was “So what?”
Not what I expected, but I took it as a challenge to demonstrate to her the significance. I described how we are curating all of this data that has never before been properly databased and how that saves our users days if not weeks of time. I went on to discuss how those data are matched with real-world evidence of adverse event rates, and the economic impact of those adverse events.
Her response: “So what?”
I told her about recent projects that we have worked on with top tier pharmaceutical companies, helping them to demonstrate the value and impact their medications have, and how these data support drug decisions.
“So what?” she says.
I went on to explain how drug utilization and formulary decisions within health payers and large health system integrated delivery networks (IDNs) are using this new information asset to make more informed decisions, which ultimately lower health care costs and improve patient outcomes.
“Wait”, she said… “Repeat what you just said”…
I told her again about the new information asset that we’ve created and the analytic framework….
“No, no, no… tell me how this improves patient outcomes! That is what’s important!”
And then it hit me. Yes, our data and platform are used in health economic and outcomes research. Yes, they are used by health organizations to make more informed utilization and formulary decisions. And yes… the data and platform that we have created here at Advera Health has the power to improve patient outcomes. This isn’t something new. It was the original driving force to founding Advera Health back in 2010, and remains a central part of our philosophy. However, that philosophy admittedly gets muddled by all of the daily “trees” that are in the way.
So, with the launch of clinical evidence on multiple sclerosis drugs in Evidex, rather than write a blog post on the technological and labor intensive work that went into creating the data asset (a lot), or focusing on a HEOR/Market Access use case (there are great ones), or how this dataset can save weeks of time during a drug review (it will), I will provide three ways in which our clinical evidence database on multiple sclerosis drugs will improve patient outcomes.
More accessible drug evidence equals better treatment decisions.
Multiple sclerosis is a terrible disease with numerous treatment options. Making decisions about those treatment options with up-to-date, easily accessible evidence leads healthcare decision makers to better choices. Informed choices not only ensure that each patient gets the treatment that is right for them, but ensures that proper evidence based information on risk/benefit is available, thus improving patient outcomes.
Real-world drug safety data empowers risk adjusted treatment algorithms, minimizing adverse event impact to patients
It is a well-known fact a drug’s true safety profile is not fully understood until it is on market. Understanding how the evidence pool for a drug has evolved from clinical trial to real world leads healthcare decision makers to design utilization strategies that minimize patient harm.
Transparent drug evidence leads to aligned interests, which lead to better patient outcomes
All stakeholders, including drug manufactures, payers, plan sponsors, healthcare delivery, and patients must have easy access to the best data possible in order to be aligned. Once all stakeholders are aligned in the drug decision making process, the best treatment choices possible can be made.
With the release our clinical evidence module on our Evidex platform, which includes coverage of hepatitis C, diabetes, and now multiple sclerosis we have created ways for our clients to do their job better. Drug manufacturers are using our datasets and analytics to generate evidence that is used by managed care. Payers, plans and health systems are using that same data to drive their reimbursement and utilization decisions. And, healthcare providers and clinical pharmacists are using that data at the point of care as well.
But ultimately, looking at the forest, I can see that by launching our clinical evidence dataset and pairing it with real-world safety data, we have made significant and important strides to improve patient outcomes.
I invite our readers to see our latest Drug Evidence Review on the pipleine multiple sclerosis medication, Zinbryta.
We will also be at the ISPOR conference in Washington D.C. next week. Booth 102 and our VP of Scientific Affairs, Dr. Keith Hoffman will be presenting his poster, Hepatitis C Medications: Estimating the Costs of Adverse Drug Reactions and Poor Patient Outcomes on Tuesday, May 24th from 3:45 PM - 7:45 PM in the Columbia Room (Terrace Level).
Jim Davis, EVP Advera Health Analytics, Inc.